Form 4: Blueprint Medicines COO Christina Rossi Sells Shares Under 10b5-1 Trading Plan

Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold a total of 2,274 shares of common stock on May 19, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Christina Rossi, the Chief Operating Officer of Blueprint Medicines Corp, reported the sale of company stock on May 19, 2025.
• The sales were executed under a pre-arranged trading plan (Rule 10b5-1) adopted on August 27, 2024.
• A total of 2,274 shares of common stock were sold in multiple transactions at varying prices.
• The prices ranged from $99.42 to $101.90 per share.
• Following the reported transactions, Rossi directly owns 64,718 shares of Blueprint Medicines Corp.
• The sales were reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting insider trading activity. The sentiment is neutral as it simply reports facts without expressing any positive or negative views about the company's performance or future prospects.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative.

Stakeholder Impact

• The stock sale may have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider information.

Key Dates

Keywords

Form 4, insider trading, stock sale, Christina Rossi, Blueprint Medicines, BPMC, Rule 10b5-1, Chief Operating Officer